Imunon (IMNN)
Developing localized DNA immunotherapy for advanced ovarian cancer.
Something off on this page? Send us feedback.
Develops non-viral DNA immunotherapies and vaccine candidates, centered on IMNN-001, a locally administered IL-12 therapy being tested with standard chemotherapy for advanced ovarian cancer; as a pre-revenue clinical-stage company, it relies on trial progress, external financing, and partners.
Develops non-viral DNA immunotherapies and vaccines through its TheraPlas and PlaCCine platforms. Its central program, IMNN-001, delivers an IL-12 DNA payload into the ovarian-tumor environment and is in a pivotal trial alongside standard chemotherapy for newly diagnosed advanced ovarian cancer. PlaCCine encodes viral antigens for vaccines, although its development and patent activity have been paused amid partnership and competitive constraints.
Operates as a single, pre-revenue research-and-development segment, running clinical-scale manufacturing in Alabama while using contract manufacturers for fill/finish and clinical supplies. Progress is concentrated in the ovarian-cancer program and depends on patient enrollment, trial execution, regulatory review, additional financing, third-party supply, and commercialization arrangements.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Maxim Group | Target | $10 | ||
| May 19, 2025 | D. Boral Capital | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.9M · Total debt $7.8M · Total assets $15.0M · Shareholders' equity $4.2M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- −$2.8M
No dividends on record.
| Institutions18 holders · as of Mar 31, 2026 | 11.98% | 503.6K shares | |
| Insiders10 holders · as of Sep 1, 2026 | 7.25% | 304.8K shares | |
| Otherremainder | 80.77% | 3.39M shares |
4.20M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.61M in the company's Sep 3, 2026 report, 4.20M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 8.29% | 348,330 | 13Fas of Mar 31, 2026 |
Stacy LindborgInsiderdirector, officer: President and CEO | 2.38% | 100,076 | Form 4filed Sep 1, 2026 ↗ |
Michael H. TardugnoInsiderdirector, officer: Executive Chairman of Board | 2.14% | 89,875 | Form 4filed Sep 1, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 1.14% | 48,056 | 13Fas of Mar 31, 2026 |
Douglas Vincent FallerInsiderofficer: Chief Medical Officer | 0.88% | 37,077 | Form 4filed Sep 1, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Susan Eylward | officer: General Counsel and Corp Sec | −2,525 | $1.56 |
| Aug 17, 2026 | Susan Eylward | officer: General Counsel and Corp Sec | −2,449 | $1.63 |
| Aug 3, 2026 | Susan Eylward | officer: General Counsel and Corp Sec | −2,541 | $1.57 |
| Jul 20, 2026 | Susan Eylward | officer: General Counsel and Corp Sec | −2,150 | $1.78 |
| Jul 6, 2026 | Susan Eylward | officer: General Counsel and Corp Sec | −920 | $1.88 |
- Merck
First-line Phase 3 immunotherapy and PARP-maintenance regimen.
- AstraZeneca (ADR)
PARP maintenance and immunotherapy combinations in first-line ovarian care.
- GSK (ADR)
Approved PARP maintenance and Phase 3 immunotherapy combination.
- Pfizer
Front-line bevacizumab biosimilar for advanced ovarian cancer.
- AbbVie
Targeted ADC option in FRα-positive platinum-resistant ovarian cancer.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Imunon | $1.58 | −1.56% | $6.6M | — | — | — | — |
| Merck | $151.58 | −0.04% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| AstraZeneca (ADR) | $163.88 | +1.37% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| GSK (ADR) | $50.65 | +0.45% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Pfizer | $29.00 | −0.10% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Median | 38.3 | 15.2 | 4.1 | +5.1% |